<DOC>
	<DOCNO>NCT02334293</DOCNO>
	<brief_summary>The purpose study determine fat emulsion comprise omega-3 fatty acid , Omegaven , would beneficial management steatotic liver injury parenteral nutrition ( PN ) inhibition de novo lipogenesis , reduction arachidonic acid-derived inflammatory mediator , prevention essential fatty acid deficiency presence small amount arachidonic acid , improve clearance lipid serum .</brief_summary>
	<brief_title>Omegaven® Parenteral Nutrition</brief_title>
	<detailed_description />
	<mesh_term>Cholestasis</mesh_term>
	<criteria>Greater 14 day old . Have PNassociated cholestasis define least 2 consecutive direct bilirubin &gt; 2 mg/dL anatomical functional short gut ( OR &gt; 4 mg/dL intact intestine ) obtain least 1 week apart ratio direct : total bilirubin &gt; 0.4 . Patients PN dependent ( unable meet nutritional need solely enteral nutrition ) expect require PN least 4 week . Patients must fail standard therapy Parenteral Nutrition Associated Liver Disease ( PNALD ) include : cycling PN , avoid overfeeding , reduction/removal copper manganese PN , advancement enteral feeding , use ursodiol ( i.e . Actigall ) . Signed patient inform consent . The patient expect reasonable possibility survival . No known etiology cholestasis PNALD time Omegaven® initiation . Causes cholestasis PNALD include limited Hepatitis C , Cystic fibrosis , biliary atresia , alpha 1 antitrypsin deficiency , prior Omegaven® initiation . Known fish egg allergy Any contraindication use Omegaven® : 1 . Active new infection time initiation Omegaven® 2 . Hemodynamic instability 3 . Use medication associate risk bleeding , include nonsteroidal antiinflammatory drug ( NSAIDs ) 4 . Active coagulopathy bleeding 5 . Thrombocytopenia 6 . Unstable hyperglycemia 7 . Impaired lipid metabolism ( triglyceride &gt; 1000 mg/dL ) 1 g/kg/day less Intralipid 8 . History severe hemorrhagic disorder ( ie . hemophilia , Von Willebrand disease , etc . ) 9 . Unstable diabetes mellitus 10 . Collapse shock 11 . Stroke/ Embolism 12 . Cardiac infarction within last 3 month 13 . Undefined coma status Enrollment clinical trial involve investigational agent ( unless approve designated physician multidisciplinary team ) The parent guardian child unwilling provide consent assent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>4 Months</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Omegaven</keyword>
	<keyword>parenteral nutrition</keyword>
	<keyword>liver disease</keyword>
	<keyword>liver injury</keyword>
</DOC>